logo
Plus   Neg
Share
Email

Merck: FDA Approves Second Biomarker-Based Indication For KEYTRUDA

Merck (MRK) announced the FDA has approved KEYTRUDA as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. The indication is approved under accelerated approval.

"For the second time, KEYTRUDA monotherapy is now approved based on a biomarker rather than the location in the body where the tumor originated," said Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories.

The FDA also approved FoundationOne CDx test as the companion diagnostic to identify patients with solid tumors that are TMB-H who may benefit from immunotherapy treatment with KEYTRUDA monotherapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Former Google engineer Anthony Levandowski was sentenced by a U.S. judge to eighteen months in prison for stealing trade secrets from Google's self-driving car unit before he defected to Uber's rival unit. Levandowski admitted that from 2009 to 2016, he worked in Google's self-driving car program, known then as Project Chauffer. JetBlue has strengthened its face covering policy, by prohibiting face masks with vents or exhalation valves, starting August 10. It will also no longer allow customers to claim exemptions from wearing a face covering altogether. Home Depot, Inc. is set to open three new distribution centers in Georgia over the next 18 months, which is expected to create an additional 1,000 new jobs in Greater Atlanta, including full-time and part-time positions. The home improvement retailer has already created more than 5,000 new jobs in Georgia over the last five years.
Follow RTT